|
| | 98TH GENERAL ASSEMBLY
State of Illinois
2013 and 2014 HB5526 Introduced , by Rep. Dennis M. Reboletti SYNOPSIS AS INTRODUCED: |
| 720 ILCS 570/204 | from Ch. 56 1/2, par. 1204 |
|
Amends the Illinois Controlled Substances Act. Makes kratom (including any parts of the plant Mitragyna speciosa, whether growing or not, and any compound, manufacture, salt, derivative, mixture, or preparation of that plant, including but not limited to mitragynine and 7-hydroxymitragynine) a Schedule I controlled substance.
|
| |
| | | CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY | |
| | A BILL FOR |
|
|
| | HB5526 | | LRB098 15322 RLC 50351 b |
|
|
1 | | AN ACT concerning criminal law.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Illinois Controlled Substances Act is |
5 | | amended by changing Section 204 as follows: |
6 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) |
7 | | Sec. 204. (a) The controlled substances listed in this |
8 | | Section are
included in Schedule I. |
9 | | (b) Unless specifically excepted or unless listed in |
10 | | another
schedule, any of the following opiates, including their |
11 | | isomers,
esters, ethers, salts, and salts of isomers, esters, |
12 | | and ethers,
whenever the existence of such isomers, esters, |
13 | | ethers and salts is
possible within the specific chemical |
14 | | designation: |
15 | | (1) Acetylmethadol; |
16 | | (1.1) Acetyl-alpha-methylfentanyl |
17 | | (N-[1-(1-methyl-2-phenethyl)-
|
18 | | 4-piperidinyl]-N-phenylacetamide); |
19 | | (2) Allylprodine; |
20 | | (3) Alphacetylmethadol, except
|
21 | | levo-alphacetylmethadol (also known as levo-alpha-
|
22 | | acetylmethadol, levomethadyl acetate, or LAAM); |
23 | | (4) Alphameprodine; |
|
| | HB5526 | - 2 - | LRB098 15322 RLC 50351 b |
|
|
1 | | (5) Alphamethadol; |
2 | | (6) Alpha-methylfentanyl
|
3 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
|
4 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
|
5 | | propanilido) piperidine; |
6 | | (6.1) Alpha-methylthiofentanyl
|
7 | | (N-[1-methyl-2-(2-thienyl)ethyl-
|
8 | | 4-piperidinyl]-N-phenylpropanamide); |
9 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); |
10 | | (7.1) PEPAP
|
11 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); |
12 | | (8) Benzethidine; |
13 | | (9) Betacetylmethadol; |
14 | | (9.1) Beta-hydroxyfentanyl
|
15 | | (N-[1-(2-hydroxy-2-phenethyl)-
|
16 | | 4-piperidinyl]-N-phenylpropanamide); |
17 | | (10) Betameprodine; |
18 | | (11) Betamethadol; |
19 | | (12) Betaprodine; |
20 | | (13) Clonitazene; |
21 | | (14) Dextromoramide; |
22 | | (15) Diampromide; |
23 | | (16) Diethylthiambutene; |
24 | | (17) Difenoxin; |
25 | | (18) Dimenoxadol; |
26 | | (19) Dimepheptanol; |
|
| | HB5526 | - 3 - | LRB098 15322 RLC 50351 b |
|
|
1 | | (20) Dimethylthiambutene; |
2 | | (21) Dioxaphetylbutyrate; |
3 | | (22) Dipipanone; |
4 | | (23) Ethylmethylthiambutene; |
5 | | (24) Etonitazene; |
6 | | (25) Etoxeridine; |
7 | | (26) Furethidine; |
8 | | (27) Hydroxpethidine; |
9 | | (28) Ketobemidone; |
10 | | (29) Levomoramide; |
11 | | (30) Levophenacylmorphan; |
12 | | (31) 3-Methylfentanyl
|
13 | | (N-[3-methyl-1-(2-phenylethyl)-
|
14 | | 4-piperidyl]-N-phenylpropanamide); |
15 | | (31.1) 3-Methylthiofentanyl
|
16 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
|
17 | | 4-piperidinyl]-N-phenylpropanamide); |
18 | | (32) Morpheridine; |
19 | | (33) Noracymethadol; |
20 | | (34) Norlevorphanol; |
21 | | (35) Normethadone; |
22 | | (36) Norpipanone; |
23 | | (36.1) Para-fluorofentanyl
|
24 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
|
25 | | 4-piperidinyl]propanamide); |
26 | | (37) Phenadoxone; |
|
| | HB5526 | - 4 - | LRB098 15322 RLC 50351 b |
|
|
1 | | (38) Phenampromide; |
2 | | (39) Phenomorphan; |
3 | | (40) Phenoperidine; |
4 | | (41) Piritramide; |
5 | | (42) Proheptazine; |
6 | | (43) Properidine; |
7 | | (44) Propiram; |
8 | | (45) Racemoramide; |
9 | | (45.1) Thiofentanyl
|
10 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
|
11 | | 4-piperidinyl]-propanamide); |
12 | | (46) Tilidine; |
13 | | (47) Trimeperidine; |
14 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
|
15 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
|
16 | | N-phenylpropanamide). |
17 | | (c) Unless specifically excepted or unless listed in |
18 | | another
schedule, any of the following opium derivatives, its |
19 | | salts, isomers
and salts of isomers, whenever the existence of |
20 | | such salts, isomers and
salts of isomers is possible within the |
21 | | specific chemical designation: |
22 | | (1) Acetorphine; |
23 | | (2) Acetyldihydrocodeine; |
24 | | (3) Benzylmorphine; |
25 | | (4) Codeine methylbromide; |
26 | | (5) Codeine-N-Oxide; |
|
| | HB5526 | - 5 - | LRB098 15322 RLC 50351 b |
|
|
1 | | (6) Cyprenorphine; |
2 | | (7) Desomorphine; |
3 | | (8) Diacetyldihydromorphine (Dihydroheroin); |
4 | | (9) Dihydromorphine; |
5 | | (10) Drotebanol; |
6 | | (11) Etorphine (except hydrochloride salt); |
7 | | (12) Heroin; |
8 | | (13) Hydromorphinol; |
9 | | (14) Methyldesorphine; |
10 | | (15) Methyldihydromorphine; |
11 | | (16) Morphine methylbromide; |
12 | | (17) Morphine methylsulfonate; |
13 | | (18) Morphine-N-Oxide; |
14 | | (19) Myrophine; |
15 | | (20) Nicocodeine; |
16 | | (21) Nicomorphine; |
17 | | (22) Normorphine; |
18 | | (23) Pholcodine; |
19 | | (24) Thebacon. |
20 | | (d) Unless specifically excepted or unless listed in |
21 | | another
schedule, any material, compound, mixture, or |
22 | | preparation which contains
any quantity of the following |
23 | | hallucinogenic substances, or which
contains any of its salts, |
24 | | isomers and salts of isomers, whenever the
existence of such |
25 | | salts, isomers, and salts of isomers is possible
within the |
26 | | specific chemical designation (for the purposes of this
|
|
| | HB5526 | - 6 - | LRB098 15322 RLC 50351 b |
|
|
1 | | paragraph only, the term "isomer" includes the optical, |
2 | | position and
geometric isomers): |
3 | | (1) 3,4-methylenedioxyamphetamine
|
4 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
|
5 | | methylenedioxyamphetamine, MDA); |
6 | | (1.1) Alpha-ethyltryptamine
|
7 | | (some trade or other names: etryptamine;
|
8 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
|
9 | | 3-(2-aminobutyl)indole; a-ET; and AET); |
10 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); |
11 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
12 | | (also known as: N-ethyl-alpha-methyl-
|
13 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
|
14 | | and MDEA); |
15 | | (2.2) N-Benzylpiperazine (BZP); |
16 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); |
17 | | (4) 3,4,5-trimethoxyamphetamine (TMA); |
18 | | (5) (Blank); |
19 | | (6) Diethyltryptamine (DET); |
20 | | (7) Dimethyltryptamine (DMT); |
21 | | (7.1) 5-Methoxy-diallyltryptamine; |
22 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); |
23 | | (9) Ibogaine (some trade and other names:
|
24 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
|
25 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
26 | | indole; Tabernanthe iboga); |
|
| | HB5526 | - 7 - | LRB098 15322 RLC 50351 b |
|
|
1 | | (10) Lysergic acid diethylamide; |
2 | | (10.1) Salvinorin A; |
3 | | (10.5) Salvia divinorum (meaning all parts of the plant |
4 | | presently classified
botanically as Salvia divinorum, |
5 | | whether growing or not, the
seeds thereof, any extract from |
6 | | any part of that plant, and every compound,
manufacture, |
7 | | salts, isomers, and salts of
isomers whenever the existence |
8 | | of such salts, isomers, and salts of
isomers is possible |
9 | | within the specific chemical designation, derivative, |
10 | | mixture, or preparation of that plant, its
seeds or |
11 | | extracts);
|
12 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); |
13 | | (12) Peyote (meaning all parts of the plant presently |
14 | | classified
botanically as Lophophora williamsii
Lemaire, |
15 | | whether growing or not, the
seeds thereof, any extract from |
16 | | any part of that plant, and every compound,
manufacture, |
17 | | salts, derivative, mixture, or preparation of that plant, |
18 | | its
seeds or extracts); |
19 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); |
20 | | (14) N-methyl-3-piperidyl benzilate; |
21 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
|
22 | | (also known as N-hydroxy-alpha-methyl-
|
23 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
24 | | (15) Parahexyl; some trade or other names:
|
25 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
26 | | dibenzo (b,d) pyran; Synhexyl; |
|
| | HB5526 | - 8 - | LRB098 15322 RLC 50351 b |
|
|
1 | | (16) Psilocybin; |
2 | | (17) Psilocyn; |
3 | | (18) Alpha-methyltryptamine (AMT); |
4 | | (19) 2,5-dimethoxyamphetamine
|
5 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); |
6 | | (20) 4-bromo-2,5-dimethoxyamphetamine
|
7 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
|
8 | | 4-bromo-2,5-DMA); |
9 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
|
10 | | Some trade or other names: 2-(4-bromo-
|
11 | | 2,5-dimethoxyphenyl)-1-aminoethane;
|
12 | | alpha-desmethyl DOB, 2CB, Nexus; |
13 | | (21) 4-methoxyamphetamine
|
14 | | (4-methoxy-alpha-methylphenethylamine;
|
15 | | paramethoxyamphetamine; PMA); |
16 | | (22) (Blank); |
17 | | (23) Ethylamine analog of phencyclidine.
|
18 | | Some trade or other names:
|
19 | | N-ethyl-1-phenylcyclohexylamine,
|
20 | | (1-phenylcyclohexyl) ethylamine,
|
21 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; |
22 | | (24) Pyrrolidine analog of phencyclidine. Some trade |
23 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
24 | | PHP; |
25 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; |
26 | | (26) 2,5-dimethoxy-4-ethylamphetamine
|
|
| | HB5526 | - 9 - | LRB098 15322 RLC 50351 b |
|
|
1 | | (another name: DOET); |
2 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
3 | | (another name: TCPy); |
4 | | (28) (Blank); |
5 | | (29) Thiophene analog of phencyclidine (some trade
|
6 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
|
7 | | 2-thienyl analog of phencyclidine; TPCP; TCP); |
8 | | (30) Bufotenine (some trade or other names:
|
9 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
|
10 | | 3-(2-dimethylaminoethyl)-5-indolol;
|
11 | | 5-hydroxy-N,N-dimethyltryptamine;
|
12 | | N,N-dimethylserotonin; mappine); |
13 | | (31) 1-Pentyl-3-(1-naphthoyl)indole |
14 | | Some trade or other names: JWH-018; |
15 | | (32) 1-Butyl-3-(1-naphthoyl)indole |
16 | | Some trade or other names: JWH-073; |
17 | | (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- |
18 | | (2-iodophenyl)methanone |
19 | | Some trade or other names: AM-694; |
20 | | (34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- |
21 | | (2-methyloctan-2-yl)phenol |
22 | | Some trade or other names: CP 47,497 |
23 | | and its C6, C8 and C9 homologs; |
24 | | (34.5) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- |
25 | | (2-methyloctan-2-yl)phenol), where side chain n=5; |
26 | | and homologues where side chain n=4, 6, or 7; Some |
|
| | HB5526 | - 10 - | LRB098 15322 RLC 50351 b |
|
|
1 | | trade or other names: CP 47,497; |
2 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- |
3 | | (2-methyloctan-2-yl)-6a,7, |
4 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol |
5 | | Some trade or other names: HU-210; |
6 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- |
7 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- |
8 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, |
9 | | salts, and salts of isomers; Some trade or other |
10 | | names: HU-210, Dexanabinol; |
11 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- |
12 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- |
13 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
14 | | Some trade or other names: HU-211; |
15 | | (37) (2-methyl-1-propyl-1H-indol- |
16 | | 3-yl)-1-naphthalenyl-methanone |
17 | | Some trade or other names: JWH-015; |
18 | | (38) 4-methoxynaphthalen-1-yl- |
19 | | (1-pentylindol-3-yl)methanone |
20 | | Some trade or other names: JWH-081; |
21 | | (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole |
22 | | Some trade or other names: JWH-122; |
23 | | (40) 2-(2-methylphenyl)-1-(1-pentyl- |
24 | | 1H-indol-3-yl)-ethanone |
25 | | Some trade or other names: JWH-251; |
26 | | (41) 1-(2-cyclohexylethyl)-3- |
|
| | HB5526 | - 11 - | LRB098 15322 RLC 50351 b |
|
|
1 | | (2-methoxyphenylacetyl)indole |
2 | | Some trade or other names: RCS-8, BTW-8 and SR-18; |
3 | | (42) Any compound structurally derived from |
4 | | 3-(1-naphthoyl)indole or 1H-indol-3-yl- |
5 | | (1-naphthyl)methane by substitution at the |
6 | | nitrogen atom of the indole ring by alkyl, haloalkyl, |
7 | | alkenyl, cycloalkylmethyl, cycloalkylethyl or |
8 | | 2-(4-morpholinyl)ethyl whether or not further |
9 | | substituted in the indole ring to any extent, whether |
10 | | or not substituted in the naphthyl ring to any extent; |
11 | | (43) Any compound structurally derived from |
12 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen |
13 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, |
14 | | cycloalkylmethyl, cycloalkylethyl or |
15 | | 2-(4-morpholinyl)ethyl, whether or not further |
16 | | substituted in the pyrrole ring to any extent, whether |
17 | | or not substituted in the naphthyl ring to any extent; |
18 | | (44) Any compound structurally derived from |
19 | | 1-(1-naphthylmethyl)indene by substitution |
20 | | at the 3-position of the indene ring by alkyl, haloalkyl, |
21 | | alkenyl, cycloalkylmethyl, cycloalkylethyl or |
22 | | 2-(4-morpholinyl)ethyl whether or not further |
23 | | substituted in the indene ring to any extent, whether |
24 | | or not substituted in the naphthyl ring to any extent; |
25 | | (45) Any compound structurally derived from |
26 | | 3-phenylacetylindole by substitution at the |
|
| | HB5526 | - 12 - | LRB098 15322 RLC 50351 b |
|
|
1 | | nitrogen atom of the indole ring with alkyl, haloalkyl, |
2 | | alkenyl, cycloalkylmethyl, cycloalkylethyl or |
3 | | 2-(4-morpholinyl)ethyl, whether or not further |
4 | | substituted in the indole ring to any extent, whether |
5 | | or not substituted in the phenyl ring to any extent; |
6 | | (46) Any compound structurally derived from |
7 | | 2-(3-hydroxycyclohexyl)phenol by substitution |
8 | | at the 5-position of the phenolic ring by alkyl, |
9 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl |
10 | | or 2-(4-morpholinyl)ethyl, whether or not substituted |
11 | | in the cyclohexyl ring to any extent; |
12 | | (47) 3,4-Methylenedioxymethcathinone |
13 | | Some trade or other names: Methylone; |
14 | | (48) 3,4-Methyenedioxypyrovalerone |
15 | | Some trade or other names: MDPV; |
16 | | (49) 4-Methylmethcathinone |
17 | | Some trade or other names: Mephedrone; |
18 | | (50) 4-methoxymethcathinone; |
19 | | (51) 4-Fluoromethcathinone; |
20 | | (52) 3-Fluoromethcathinone; |
21 | | (53) 2,5-Dimethoxy-4-(n)-propylthio- |
22 | | phenethylamine; |
23 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; |
24 | | (55) Pentedrone. |
25 | | (e) Unless specifically excepted or unless listed in |
26 | | another
schedule, any material, compound, mixture, or |
|
| | HB5526 | - 13 - | LRB098 15322 RLC 50351 b |
|
|
1 | | preparation which contains
any quantity of the following |
2 | | substances having a depressant effect on
the central nervous |
3 | | system, including its salts, isomers, and salts of
isomers |
4 | | whenever the existence of such salts, isomers, and salts of
|
5 | | isomers is possible within the specific chemical designation: |
6 | | (1) mecloqualone; |
7 | | (2) methaqualone; and |
8 | | (3) gamma hydroxybutyric acid. |
9 | | (f) Unless specifically excepted or unless listed in |
10 | | another schedule,
any material, compound, mixture, or |
11 | | preparation which contains any quantity
of the following |
12 | | substances having a stimulant effect on the central nervous
|
13 | | system, including its salts, isomers, and salts of isomers: |
14 | | (1) Fenethylline; |
15 | | (2) N-ethylamphetamine; |
16 | | (3) Aminorex (some other names:
|
17 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
|
18 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
|
19 | | salts, optical isomers, and salts of optical isomers; |
20 | | (4) Methcathinone (some other names:
|
21 | | 2-methylamino-1-phenylpropan-1-one;
|
22 | | Ephedrone; 2-(methylamino)-propiophenone;
|
23 | | alpha-(methylamino)propiophenone; N-methylcathinone;
|
24 | | methycathinone; Monomethylpropion; UR 1431) and its
|
25 | | salts, optical isomers, and salts of optical isomers; |
26 | | (5) Cathinone (some trade or other names:
|
|
| | HB5526 | - 14 - | LRB098 15322 RLC 50351 b |
|
|
1 | | 2-aminopropiophenone; alpha-aminopropiophenone;
|
2 | | 2-amino-1-phenyl-propanone; norephedrone); |
3 | | (6) N,N-dimethylamphetamine (also known as:
|
4 | | N,N-alpha-trimethyl-benzeneethanamine;
|
5 | | N,N-alpha-trimethylphenethylamine); |
6 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
|
7 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); |
8 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV). |
9 | | (g) Temporary listing of substances subject to emergency |
10 | | scheduling.
Any material, compound, mixture, or preparation |
11 | | that contains any quantity
of the following substances: |
12 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
|
13 | | (benzylfentanyl), its optical isomers, isomers, salts,
|
14 | | and salts of isomers; |
15 | | (2) N-[1(2-thienyl)
|
16 | | methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
|
17 | | its optical isomers, salts, and salts of isomers. |
18 | | (h) Unless specifically excepted or unless listed in |
19 | | another schedule,
any material, compound, mixture, or |
20 | | preparation which contains any quantity
of kratom (including |
21 | | any parts of the plant Mitragyna speciosa, whether growing or |
22 | | not, and any compound, manufacture, salt, derivative, mixture, |
23 | | or preparation of that plant, including but not limited to |
24 | | mitragynine and 7-hydroxymitragynine). |
25 | | (Source: P.A. 96-347, eff. 1-1-10; 96-1285, eff. 1-1-11; |
26 | | 97-192, eff. 7-22-11; 97-193, eff. 1-1-12; 97-194, eff. |